Using EpCAM+/Vimentin+ specific immunomagnetic beads for CTC isolation from 174 cancer patients (118 stage I/II), Huang et al. showed that the mean CTC count in lung, colorectal, gastric, liver, and esophageal cancers was significantly higher when compared to healthy individuals and non-cancer patients with high-risk conditions, also discriminating between the latter two groups of samples [92]. Here, EPCAM is linked to cancer.